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Disclosures: C.M.S. has a financial interest in UbiVac CMV, for the development of 28 spread-defective CMV-based therapeutics. Neither the funding bodies nor UbiVac CMV 29 had any role in the design of the experiments or the interpretation of data. 30 31 was substantially blunted in Rag-deficient animals. However, viral spread was not needed 48 and a spread-defective MCMV strain was equally effective. In most mice, the anti-tumor 49 effect of MCMV was transient. Although the recruited macrophages persisted, tumor 50 regrowth correlated with a loss of viral activity in the tumor. However, an additional 51 round of MCMV infection further delayed tumor growth, suggesting that tumor growth 52 delay was dependent on active viral infection. Together, our results suggest that MCMV 53 infection delayed the growth of an immunologically "cold" tumor by recruiting and 54 modulating macrophages in order to promote anti-tumor immune responses. 55 situations. Work from the Reddehase lab suggested that CMV infection may delay the 103 growth of lymphoma in the liver [48] [49] [50] . Likewise, we recently showed that intra-tumoral 104 (IT)-injection of murine (M)CMV into poorly immunogenic B16 melanomas resulted in 105 delayed tumor growth 51 . Finally, the Herbein lab demonstrated that human (H)CMV 106 could inhibit the growth of hepatocellular carcinoma as well activate pathways involved 107 in tumorigenesis 52, 53 . Thus, it is unclear how CMV may affect the tumor environment and 108 how these effects vary based on the type of tumor. 109 110 Given the disparate effects of CMV on various cancers, we wished to define the 111 mechanism by which MCMV delayed tumor growth in the melanoma model. 112
Importantly, the primary infected cells in the tumor were macrophages 51 , hinting that the 113 virus was not oncolytic. Macrophages and other myeloid cells are important for the 114 biology of CMV [54] [55] [56] [57] [58] [59] [60] , which utilizes these cells for systemic dissemination and as sites of 115 latency. Thus, CMV has evolved mechanisms to recruit monocytes to the site of infection 116 and alter their functional state. Additionally, tumor-associated macrophages (TAMs) 117 have emerged as key regulators of the tumor microenvironment where they are 118 predominantly anti-inflammatory or M2-like, and support tumor growth 61-63 . Recent 119 work has shown that depleting these M2-like macrophages from the tumor or converting 120 them to a more pro-inflammatory, or M1-like, state can induce tumor regression [64] [65] [66] [67] . 121
Thus, the goal of the present study was to define how MCMV modulated TAMs and 122 whether the virus' interaction with TAMs was important for delaying tumor growth in the 123 melanoma model. 124 frozen batch were thawed, passaged once more, and implanted within seven days. 148
Injected cells were always pigmented and the batch was certified negative for 149 mycoplasma and other pathogens by IMPACT III testing on 10/30/2017 by IDEXX 150
BioResearch. For tumor implantation, B16-F0s were resuspended in HBSS and injected 151 subcutaneously in the shaved right flank of the animal as described previously 68 . Tumor 152 growth was monitored by measuring length and width with a 6-inch digital caliper 153 (Neiko). When tumors reached 20mm 2 in area they were directly injected with MCMV or 154 PBS as a control using an insulin syringe with 5x10 5 pfu of virus in 30 µL of PBS, every 155 other day for a total of three injections. WT-MCMV (K181) and spread-defective 156 MCMV (ΔgL, based on the K181 backbone 10 ), have been previously described. Viruses 157 expressing an MCK2 with mutations in the chemokine domain (RM4511, hereafter called 158 MCK2 mut ), or its matched wild-type counterpart (RM4503, hereafter called MCK2 WT ), as 159 well as a virus completely lacking MCK2 (RM461, referred to as MCK2 KO) and its 160 matched counterpart (RM427, referred to as MCK2 WT) were kindly provided by Dr. 161
Edward Mocarski 69 . All viruses were grown as previously described 70 . After IT 162 injections, tumors were monitored until they reached 100 mm 2 . 163 Clodronate depletion. To deplete monocytic phagocytes, clodronate liposomes 164 (Liposoma B.V., Amsterdam) were diluted in PBS and injected at a concentration of 10 165 mg/kg IP and 5 mg/kg IT as previously described 64 . Liposomes were injected beginning 1 166 day before intratumoral injections (e.g. day -1) and were repeated on days 2, 4, 7 and 11 167 or until sacrifice if tumors reached 100mm 2 before day 11. The amount of liposomes was 168 adjusted weekly based on animal weight. Bone marrow culture and in vitro viral infections. L929-conditioned media for growing 179 macrophages was produced by plating 7.2x10 5 L929 cells in T-150 flasks. Supernatant 180 was harvested after 7 days, replaced with fresh media and harvested again after 14 days. 181
All L929 conditioned media was combined and frozen for later use. The bone marrow 182 from femurs and tibias of C57BL/6J mice was flushed and incubated in bone marrow 183 macrophage media consisting of DMEM with 10% L929-conditioned media, 10% fetal 184 bovine serum, and 1% penicillin-streptomycin. Non-tissue culture treated petri dishes 185 were used to facilitate macrophage recovery from the plastic. On day 7 of the culture, 186 macrophages were re-plated at 6x10 5 cells/well in a 6 well plate. M2-like macrophages 187 were polarized using 40 ng/mL IL-4 on day 8. On day 9, MCMV was added at a 188 multiplicity of infection (MOI) of 5 to half of the IL-4-treated wells without removing the 189 polarizing media. For comparison, M1-like macrophages were polarized by adding 20 190 ng/mL of IFN-γ and 1 µg/mL LPS on day 9 of culture in parallel wells. 24 hours after 191 infection, all macrophages were harvested for analysis.
To test the ability of MCK2 mut MCMV and its wild-type counterpart to infect 193 macrophages ( Figure 4E ), bone marrow derived macrophages (BMDMs) were produced 194 as above and infected with either virus at an MOI of 1 on the 8th day of culture (with no 195 cytokines added for polarization). After 24 hours, the cells were fixed and permeabilized 196 with a 1x dilution of True-Nuclear Transcription Factor kit (BioLegend) following the 197 manufacturer's instructions. Cells were blocked overnight in PBS with 0.2% BSA, 0.1% 198 gelatin, and 0.1% Triton X-100 and then stained for expression of MCMV pp89 using 199 clone 6/58/1 71 for 1 hour, followed by anti-mouse IgG2b (clone RMG2b-1, BioLegend). Data Availability. All data is freely available upon request. RPPA data can be found in 254 Supplemental Table 1 . 255
Results 256
Intratumoral injections of WT-MCMV lead to delayed tumor growth 257
We have previously reported that IT injections of MCMV lead to delayed growth of 258 established B16-F0 melanomas. In this treatment schedule, MCMV was injected directly into the melanoma lesions every other day for a total of three injections beginning once 260 the tumors reached approximately 20mm 2 in area ( Figure 1A ) 76 . Consistent with our 261 previous data, injections of WT-MCMV delayed tumor growth and significantly 262 prolonged the time for tumors to reach the pre-determined end point of 100mm 2 ( Figure  263 1B-C). Median survival after reaching 20 mm 2 was 9 days for the mice treated with IT-264 PBS and 19.5 days for mice treated with IT-MCMV. Tumor doubling-time was also 265 assessed by linear regression of log-transformed growth data. This is a less sensitive 266 measure of tumor growth since it includes data points from the exponential growth phase 267 after treatment and excludes animals that clear their tumors. Nevertheless, tumor 268 doubling time was significantly increased by IT-MCMV injections ( Figure 1D ). Moreover, these data strongly argue that MCMV is not acting as an oncolytic virus in this 275 model since even a spread-defective version of MCMV was similarly able to delay tumor 276 growth. 277 278
Monocytic phagocytes are necessary but not sufficient for tumor growth delay 279
Our previous data showed that MCMV preferentially infected TAMs in this model 76 . In 280 order to determine the importance of TAMs, we depleted phagocytic cells with 281 clodronate-filled liposomes delivered IP and IT as described in the materials and methods. Depletion of phagocytes had no effect on the growth of tumors treated with IT-283 PBS ( We previously showed that antibody depletion of CD8+ cells, which includes both T 294 cells and dendritic cells, ablated the efficacy of IT-MCMV 76 . Since our new data show 295 that clodronate depletion of phagocytes prevented MCMV from delaying tumor growth, 296 it remained possible that anti-CD8 antibodies accelerated tumor growth by depleting 297 CD8+ dendritic cells. Thus, to confirm that adaptive immune cells are required for tumor 298 growth delay, we tested the efficacy of IT injections of spread-defective MCMV in Rag 299 KO animals. Interestingly, treatment had a small, but significant effect on survival and 300 tumor doubling times ( Figure 3A -C). Nevertheless, efficacy was severely blunted in these 301
Rag KO mice, with a median survival of only 13 days ( Figure 3B ). These data confirm 302 that adaptive immune mechanisms are required for anti-tumor immunity in addition to 303 monocytic phagocytes. 304
MCK2 mediated recruitment of new macrophages is indispensable for tumor 306 growth delay 307
The MCMV encoded chemokine MCK2 has been implicated in the recruitment of 308 monocytes to the site of infection 77-79 . Thus, we hypothesized that MCK2 might be a 309 critical regulator of MCMV driven anti-tumor immunity. To test this, we used a mutant 310 MCMV in which the dual cysteines of the chemokine domain of MCK2 were mutated 311 (MCK2 mut ) along with a matched wild-type strain (hereafter called MCK2 WT ) 69 . 312
Remarkably, the MCK2 mut MCMV was significantly less effective at delaying tumor 313 growth or increasing survival when compared to the MCK2 WT virus ( Figure 4A -C). IT 314 treatment with MCK2 mut MCMV still increased animal survival and tumor doubling 315 times compared to PBS-treated tumors, although the effects were less dramatic. MCK2 316 has been implicated in the entry of MCMV into macrophages 79 . However, the MCK2 mut 317 virus was able to infect macrophages equally to its wild-type counterpart ( Figure 4E ). 318
Therefore, these data strongly suggest that MCK2 was required to recruit macrophages 319 into the tumor. Importantly, we repeated this experiment with a second, independently 320 generated mutant MCMV that completely lacked MCK2 (MCK2 KO) compared to its 321 matched wild-type control virus. This virus completely lacking MCK2 exhibited an even 322 more striking loss of therapeutic efficacy, with no increase in survival or doubling time 323 compared to PBS-treated tumors ( Figure 4F Additionally, we noted that macrophages seemed to infiltrate into the center of tumors 331 treated with the MCK2 WT virus compared to MCK2 mut virus (Supplemental Figure 2) , 332
suggesting that MCK2 may impact both the number and localization of TAMs after IT 333 infection. 334
335

MCMV infection re-polarizes macrophages to become more inflammatory 336
In order to better understand the effect MCMV infection was having on the recruited 337 macrophages, we produced bone marrow derived macrophages (BMDMs) and either left 338 them unpolarized (M0), or polarized them to an M2-like or an M1-like state as described 339
in the materials and methods. After polarization, each sub-type was infected with MCMV 340 and we assessed changes in the expression of various transcripts relative to uninfected 341 M0 macrophages. The data show a trend of MCMV infection driving cells towards a 342 more M1-like state (increased iNOS, increased TNF-α, reduced arginase), with changes 343 in iNOS reaching statistical significance ( Figure 5A) . 344
345
For a more comprehensive analysis, we used reverse phase protein array (RPPA), a 346 quantitative proteomics approach. For this, BMDMs were cultured and infected as above, 347 and cell lysates were subjected to RPPA analysis. Unsupervised clustering of protein 348 quantitation shows that M1-like macrophages are distinct from both M0 and M2-like 349 macrophages ( Figure 5B ). However, infection of both M0 and M2 macrophages led them 350 to be clustered with M1 macrophages and with MCMV-infected M1 macrophages. We also used a Monocle pseudotime plot to define trajectories of differentiation between 352 each cell population. As shown in Figure 5C To validate the RPPA data, we chose to assess the phosphorylation of S6, which was 359 strongly increased by MCMV infection in the RPPA analysis ( Figure 5B ). We could 360 clearly detect an increase in S6 phosphorylation by flow cytometry after MCMV 361 infection (Supplemental Figure 1C) , which is consistent with previous work using human 362 (H)CMV 80 . Overall, these data indicate that MCMV has the ability to re-polarize M2-like 363 macrophages toward a more inflammatory state. The effect of IT-MCMV is transient and tumors began to regrow in most mice 368 approximately 7-10 days after therapy began. We harvested tumors on days 5, 8 and 11 369 after the start of IT therapy and found that expression levels of iNOS, TNF-α, IL-1β, 370 arginase and IL-10 were all increased by day 5 after the first IT-MCMV injection (Figure  371 6A). Inflammatory transcripts (iNOS, TNF-α, IL-1β) also seemed to be sustained at 372 higher levels on Day 8, but did not reach significance over PBS. The specific contribution 373 of TAMs to these transcripts could not be directly assessed because baseline levels of 374 these transcripts were increased by clodronate liposomes alone (not shown). Regardless, these changes were transient: by day 11, all transcripts had returned to the baseline levels 376 seen in PBS-treated tumors. This time-point correlates with a loss of viral transcription in 377 the tumor ( Figure 6B ) and approximately aligns with the beginning of tumor regrowth 378 (e.g. Figure 1 ). Thus, the inflammatory changes associated with a therapeutic effect were 379 not sustained as the virus was controlled. Additionally, we recovered TAMs at all 3 time 380 points and assessed their phenotype by flow cytometry (Figure 6C ). Therapy with IT-381 MCMV was associated with the emergence of a distinct F4/80 hi Ly6C int macrophage 382 population on day 8. These cells expressed high levels of PD-L1 and MHC-II, indicating 383 their activation ( Figure 6D ). However, this population was no longer evident by day 11. 384
Together, these data indicate that a single round of IT-MCMV therapy transiently alters 385 the tumor microenvironment by recruiting and activating TAMs and altering the 386 inflammatory milieu. 387
388
Since the effects of IT-MCMV were transient and tumor re-growth coincided with a loss 389 of viral activity in the tumor, we wondered whether additional IT-MCMV treatment 390 would delay tumor growth further. To test this, we treated tumors with IT-MCMV as 391 above ( Figure 1A) when the therapy was no longer working as indicated by multiple days 392 of positive growth after the period of stable disease. When treated tumors re-surpassed a 393 size of 20mm 2 , the animals received 3 additional injections of MCMV (denoted as 6 WT-394
MCMV) or 3 injections of PBS (denoted as 3 WT-MCMV + 3 PBS). This second round 395
of IT-MCMV therapy further delayed tumor growth and significantly improved overall 396 survival ( Figure 7A-B ). Tumor doubling times were also significantly increased to 19.2 397 days for animals that received 6 doses of IT-MCMV versus 12.2 days for 3 doses of MCMV plus 3 doses of PBS (p=0.046, not shown). Remarkably, when the time required 399 for tumors to reach 100mm 2 was normalized to the days after the last MCMV treatment 400 (the 3rd or the 6th overall injection), there was no significant difference ( Figure 7C) , 401
indicating that the second round of therapy increased overall survival by recapitulating 402 the original effect. Interestingly, tumors taken one day after the 6 th injection with WT-403 MCMV or one day after the last injection in the 3 WT-MCMV +3 PBS group showed 404 similar numbers of macrophages in the tissue (Figure 7D It is increasingly clear that viral modulation of the tumor microenvironment is a 418 promising strategy for tumor immune therapy. CMV can effectively be used as a vaccine 419 platform to generate anti-tumor immune responses in multiple models [16] [17] [18] [19] [20] [21] [22] . However, the 420 ability of CMV to infect and establish latency in myeloid cells means that any tissue or tumor that recruits monocytes will likely recruit CMV-infected monocytes. Since CMV 422 can be found in a variety of solid tumors 33,34 and it has been hypothesized that CMV may 423 promote or exacerbate tumor growth, it is important to discern the impact of CMV on 424 tumor microenvironments. We had previously observed that MCMV could delay the 425 growth of the poorly immunogenic B16 melanoma and the current study aimed to define 426 the mechanism behind this unexpected outcome. Our data suggest that viral infection 427 inhibits tumor growth by actively recruiting monocytes that become TAMs. TAMs were 428 subsequently infected and activated by infection. Therefore, we propose that MCMV 429 engages adaptive immune responses in the tumor by recruiting and activating TAMs. 430
However, once viral replication was lost, tumors began to regrow. Tumors in most mice 431 returned to an exponential growth phase beginning 7 to 10 days after the initiation of 432 therapy, which corresponded with a loss of viral activity in the tumor ( Figure 6B ). We 433 found that macrophage numbers remained elevated as tumors began to regrow and that a 434 second round of MCMV infection was able to re-delay tumor growth and increase the 435 number of mice that cleared their tumors (Figure 7) . These data suggest that active 436 MCMV infection may be the key for driving immunity that can delay tumor growth. 437
438
This study is limited to the anti-tumor effects of MCMV during an active intratumoral 439 infection in a model using tumor cells that are already transformed and are poorly 440 infected by the virus. Thus, our data do not speak to the potential of MCMV to promote 441 transformation of normal cells nor do they suggest how latency may lead to 442 oncomodulation. However, our data do indicate that virus-recruited macrophages 443 remained in the tumor. In settings where these macrophages can be converted to an anti-inflammatory M2-like state by the tumor, it is possible that the recruited macrophages 445 could ultimately support tumor growth. In our hands however, when the tumor started to 446 regrow after IT-MCMV, the tumor doubling time was still reduced (i.e. growth was still 447 slower) when compared mice that never received MCMV (data not shown). Moreover, 448
we have seen slower growth of untreated tumors in mice latently infected with MCMV 449 (data not shown). These data could indicate that latent virus may not be detrimental in 450 some cases, although further research is needed to fully define the effects of MCMV 451 latency on tumor growth and progression. Our data suggest that CMV may offer a unique tool to directly target macrophages in the 471 tumor environment through both recruitment and infection. Activation of TAMs has 472 strong potential to provide synergy with current immune therapy treatment strategies, 473 especially immune checkpoint blockades. Most people fail to respond to immune 474 checkpoint therapies in isolation 83 and immense effort is being devoted to rationally 475 design combinations of therapies that can increase the number of responding patients. 476
One of the main differences between responders and non-responders may be the degree 477 of immune infiltration into the tumor. Thus, the B16-F0 tumor model is appropriate to 478 test the virus in this context as it is very poorly immunogenic and checkpoint blockade 479 therapies are mostly ineffective 76, 85 . Our data suggest that MCMV was not acting as an 480 oncolytic virus as it did not have to spread from the infected cells to delay tumor growth 481 (Figure 1) . Moreover, tumor growth delay was markedly reduced in the absence of an 482 adaptive immune responses (Figure 3 ), suggesting that immune activation was an 483 important part of MCMV's impact on tumors. Emerging evidence suggests that immune 484 activation in the tumor environment is an important feature of both oncolytic and non-485 oncolytic pathogens used for therapy, and may improve responses to immune checkpoint 486 Representative FACS plots from B16-F0 tumors indicating the gating strategy for 600 assessing macrophage as shown in Figure 6C Figure 2 
